Athyrium Capital Management And Esperion Therapeutics Enter $50M Royalty Financing Agreement On Japanese Sales Of Bempedoic Acid Products
Esperion Therapeutics, Inc. -0.49%
Esperion Therapeutics, Inc. ESPR | 2.04 | -0.49% |
Athyrium Capital Management And Esperion Therapeutics Enter $50M Royalty Financing Agreement On Japanese Sales Of Bempedoic Acid Products
